



Insights Into Acute Myeloid Leukemia (AML) February 9, 2024

Speakers: Elias Jabbour
Tapan Kadia

AGENDA

Time (ET)	Topic
2.00 PM – 2.15 PM (15 min)	Introduction <ul style="list-style-type: none"> • Program overview • ARS questions
2.15 PM – 2.55 PM (20-min presentation; 20-min discussion)	First-line Therapy in AML <ul style="list-style-type: none"> • Overview of approach for newly diagnosed AML <ul style="list-style-type: none"> – Determining fitness for initial therapy – IC regimens – Low-intensity regimens • Role of targeted therapies <ul style="list-style-type: none"> – IDH1/2 – FLT3 – Sequencing considerations • Future directions
2.55 PM – 3.55 PM (30-min presentation; 30-min discussion)	Maintenance Therapy in AML <ul style="list-style-type: none"> • Post-intensive chemotherapy <ul style="list-style-type: none"> – Surveillance vs transplant vs maintenance • Maintenance therapy <ul style="list-style-type: none"> – Importance of maintenance therapy for patients going to transplant – Role of oral vs injectable HMAs – Azacitidine <ul style="list-style-type: none"> ▪ HOVON 97 ▪ QUAZAR AML-001 – Decitabine – Role of combination therapy • Future directions
3.55 PM – 4.05 PM (10 min)	Break
4.05 PM – 4.50 PM (45 min)	Patient Case-Based Discussion
4.50 PM – 5.00 PM (10 min)	Key Takeaways and Meeting Evaluation